[Eradication and Chronic Acid Suppression. Advances and Pseudo-advances]

Overview

Journal Internist (Berl)

Specialty General Medicine

Date 2004 Jul 3

PMID 15232691

Authors

S Turi

D Schilling

J F Riemann

Affiliations

Soon will be listed here.

Abstract

Guidelines for Helicobacter pylori therapy were proposed at the Maastricht 2/2000 conference. Since then no further major developments have been made. An evidenced based choice of treatment is thereby nearly impossible as large randomized trials have not been performed. Minor progress could be achieved in the areas of second-line and rescue treatment options after failure of the standard therapy. At present proton pump inhibitors are the most powerful drugs for the treatment of gastro-oesophageal reflux disease. No additional progress has been achieved concerning therapy of reflux disease in the last years. Reasonable anxiety about the safety of long-term acid suppression with proton pump inhibitors diminished over years as no significant increase in cancer development could be detected.

References

Sheu B, Huang J, Yang H, Huang A, Wu J . The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. Aliment Pharmacol Ther. 2003; 17(10):1283-90. DOI: 10.1046/j.1365-2036.2003.01527.x. View

Svoboda Jr A . Increasing concerns about chronic proton pump inhibitor use. J Clin Gastroenterol. 2001; 33(1):3-7. DOI: 10.1097/00004836-200107000-00002. View

Vergara M, Vallve M, Gisbert J, Calvet X . Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003; 18(6):647-54. DOI: 10.1046/j.1365-2036.2003.01746.x. View

Stedman C, Barclay M . Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000; 14(8):963-78. DOI: 10.1046/j.1365-2036.2000.00788.x. View

Gisbert J, Pajares J . Helicobacter pylori therapy: first-line options and rescue regimen. Dig Dis. 2001; 19(2):134-43. DOI: 10.1159/000050668. View

Malfertheiner P, Peitz U, Treiber G . What constitutes failure for Helicobacter pylori eradication therapy?. Can J Gastroenterol. 2003; 17 Suppl B:53B-57B. DOI: 10.1155/2003/241508. View

Huang J, Hunt R . The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther. 1999; 13(6):719-29. DOI: 10.1046/j.1365-2036.1999.00530.x. View

Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M . Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2003; (1):CD002096. DOI: 10.1002/14651858.CD002096. View

Moayyedi P, Deeks J, Talley N, Delaney B, Forman D . An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol. 2003; 98(12):2621-6. DOI: 10.1111/j.1572-0241.2003.08724.x. View

10.

Parente F, Cucino C, Bianchi Porro G . Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Dig Liver Dis. 2003; 35(8):523-8. DOI: 10.1016/s1590-8658(03)00268-8. View

11.

Tam W, Dent J . Oesophageal disorders: future developments. Best Pract Res Clin Gastroenterol. 2002; 16(6):811-33. DOI: 10.1053/bega.2002.0350. View

12.

Miehlke S, Kirsch C, Schneider-Brachert W, Haferland C, Neumeyer M, Bastlein E . A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2003; 8(4):310-9. DOI: 10.1046/j.1523-5378.2003.00158.x. View

13.

Birkner B, Hotz J, Labenz J, Monnikes H, Kolling W, Hollenz M . [Short guideline for the management of dyspepsia]. Dtsch Med Wochenschr. 2004; 129(18):1032-4. DOI: 10.1055/s-2004-824836. View

14.

Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum A . Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003; 17(12):1507-14. DOI: 10.1046/j.1365-2036.2003.01496.x. View

15.

Fakheri H, Merat S, Hosseini V, Malekzadeh R . Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003; 19(1):89-93. DOI: 10.1046/j.1365-2036.2003.01822.x. View

16.

Laine L, Ahnen D, McClain C, Solcia E, Walsh J . Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000; 14(6):651-68. DOI: 10.1046/j.1365-2036.2000.00768.x. View

17.

Edwards S, Lind T, Lundell L . Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther. 2001; 15(11):1729-36. DOI: 10.1046/j.1365-2036.2001.01128.x. View

18.

Kuipers E, Klinkenberg-Knol E, Meuwissen S . Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease. Yale J Biol Med. 2000; 72(2-3):211-8. PMC: 2579004. View

19.

Watanabe Y, Aoyama N, Shirasaka D, Maekawa S, Kuroda K, Miki I . Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy. Dig Liver Dis. 2003; 35(10):711-5. DOI: 10.1016/s1590-8658(03)00432-8. View

20.

Klinkenberg-Knol E, Nelis F, Dent J, Snel P, Mitchell B, Prichard P . Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000; 118(4):661-9. DOI: 10.1016/s0016-5085(00)70135-1. View